Disease Elimination Program, Burnet Institute, Melbourne, VIC 3004, Australia; Department of Epidemiology and Preventive Medicine, Monash University, Clayton, VIC 3008, Australia.
Department of Gastroenterology and Hepatology, Landspitali University Hospital, Reykjavik, Iceland; Faculty of Medicine, School of Health Sciences, University of Iceland, Reykjavik, Iceland.
J Hepatol. 2018 May;68(5):932-939. doi: 10.1016/j.jhep.2017.12.013. Epub 2017 Dec 21.
BACKGROUND & AIMS: In Iceland a nationwide program has been launched offering direct-acting antiviral (DAA) treatment for everyone living with hepatitis C virus (HCV). We estimate (i) the time and treatment scale-up required to achieve the World Health Organization's HCV elimination target of an 80% reduction in incidence; and (ii) the ongoing frequency of HCV testing and harm reduction coverage among people who inject drugs (PWID) required to minimize the likelihood of future HCV outbreaks occurring.
We used a dynamic compartmental model of HCV transmission, liver disease progression and the HCV cascade of care, calibrated to reproduce the epidemic of HCV in Iceland. The model was stratified according to injecting drug use status, age and stage of engagement. Four scenarios were considered for the projections.
The model estimated that an 80% reduction in domestic HCV incidence was achievable by 2030, 2025 or 2020 if a minimum of 55/1,000, 75/1,000 and 188/1,000 PWID were treated per year, respectively (a total of 22, 30 and 75 of the estimated 400 PWID in Iceland per year, respectively). Regardless of time frame, this required an increased number of PWID to be diagnosed to generate enough treatment demand, or a 20% scale-up of harm reduction services to complement treatment-as-prevention incidence reductions. When DAA scale-up was combined with annual antibody testing of PWID, the incidence reduction target was reached by 2024. Treatment scale-up with no other changes to current testing and harm reduction services reduced the basic reproduction number of HCV from 1.08 to 0.59, indicating that future outbreaks would be unlikely.
HCV elimination in Iceland is achievable by 2020 with some additional screening of PWID. Maintaining current monitoring and harm reduction services while providing ongoing access to DAA therapy for people diagnosed with HCV would ensure that outbreaks are unlikely to occur once elimination targets have been reached.
In Iceland, a nationwide program has been launched offering treatment for the entire population living with hepatitis C virus (HCV). A mathematical model was used to estimate the additional health system requirements to achieve the HCV elimination targets of the World Health Organization (WHO), as well as the year that this could occur. With some additional screening of people who inject drugs, Iceland could reach the WHO targets by 2020, becoming one of the first countries to achieve HCV elimination. The model estimated that once elimination targets were reached, maintaining current monitoring and harm reduction services while providing ongoing access to DAA therapy for people diagnosed with HCV would ensure that future HCV outbreaks are unlikely to occur.
在冰岛,一项全国性计划已启动,为所有丙型肝炎病毒(HCV)感染者提供直接作用抗病毒(DAA)治疗。我们估计:(i)实现世界卫生组织(WHO)将 HCV 发病率降低 80%的消除目标所需的时间和治疗规模扩大;以及(ii)为了最大限度地减少未来 HCV 爆发的可能性,需要对注射毒品者(PWID)进行 HCV 检测和减少伤害服务的持续频率。
我们使用 HCV 传播、肝脏疾病进展和 HCV 护理级联的动态隔室模型,对冰岛的 HCV 流行情况进行了校准。该模型根据注射毒品使用情况、年龄和参与阶段进行分层。考虑了四种方案进行预测。
该模型估计,如果每年分别对 55/1000、75/1000 和 188/1000 的 PWID 进行治疗,则可以在 2030 年、2025 年或 2020 年实现国内 HCV 发病率降低 80%的目标(分别为冰岛每年估计的 400 名 PWID 中的 22、30 和 75 名)。无论时间框架如何,这都需要对更多的 PWID 进行诊断,以产生足够的治疗需求,或者扩大 20%的减少伤害服务,以补充治疗作为预防的发病率降低。当 DAA 扩大规模与每年对 PWID 进行抗体检测相结合时,到 2024 年将达到发病率降低目标。没有对当前检测和减少伤害服务进行任何其他改变的治疗扩大规模,将 HCV 的基本繁殖数从 1.08 降低到 0.59,表明未来爆发的可能性不大。
冰岛可以在 2020 年之前通过对部分 PWID 进行额外筛查来实现 HCV 消除。维持当前的监测和减少伤害服务,同时为确诊 HCV 的人提供持续的 DAA 治疗,将确保一旦达到消除目标,就不太可能发生爆发。
在冰岛,一项为所有丙型肝炎病毒(HCV)感染者提供治疗的全国性计划已经启动。使用数学模型来估计达到世界卫生组织(WHO)的 HCV 消除目标所需的额外卫生系统需求,以及可能达到这一目标的时间。通过对一些注射毒品者进行额外筛查,冰岛可以在 2020 年之前达到世卫组织的目标,成为第一个实现 HCV 消除的国家之一。该模型估计,一旦达到消除目标,维持当前的监测和减少伤害服务,同时为确诊 HCV 的人提供持续的 DAA 治疗,将确保未来 HCV 爆发的可能性不大。